252 filings
Page 2 of 13
NT 10-Q
nsih16qc ypppn05x1
17 Feb 21
Notice of late quarterly filing
8:00am
8-K
ds1fv5thav9izo
15 Jan 21
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives
12:35pm
8-K
fijtc b82
22 Dec 20
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
9:00am
424B5
66tvu6tf fl
10 Dec 20
Prospectus supplement for primary offering
12:00am
8-K
2daba pwaegj0gxd2e26
10 Dec 20
Entry into a Material Definitive Agreement
12:00am
8-K
x7f qzyefgdp383o
16 Nov 20
Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study
12:47pm
8-K
5sgfk 7i2r
2 Nov 20
Regulation FD Disclosure
12:00pm
8-K
osj 0wkxi10uh621
2 Oct 20
Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19
12:00pm
8-K
d0av aw87
15 Sep 20
Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent
10:00am
424B5
bshzaklujga8e z1qll
4 Aug 20
Prospectus supplement for primary offering
9:32am
8-K
pn0f651
4 Aug 20
Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
9:29am
8-K
xi41nllk9vc7j5
22 Jul 20
Regulation FD Disclosure
10:00am
8-K
4n95o1okpr
20 Jul 20
Regulation FD Disclosure
3:09pm
EFFECT
woqgdb npvkl
20 Jul 20
Notice of effectiveness
12:15am
CORRESP
hjlstl
15 Jul 20
Correspondence with SEC
12:00am
UPLOAD
ijc0 t1ny
15 Jul 20
Letter from SEC
12:00am
8-K
4gu3otw
19 Jun 20
Regulation FD Disclosure
5:27pm